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Glutathione S-transferase genotype increases risk of progression
from bronchial hyperresponsiveness to asthma in adults
Abstract
BACKGROUND: Bronchial hyperresponsiveness (BHR) and variation in glutathione S-transferase
(GST) genes have been associated with asthma risk. The relationship of these two risk factors with adult
onset asthma in the general population was investigated. METHODS: GSTP1 Ile105Val single
nucleotide polymorphism and GSTM1 and GSTT1 gene deletion polymorphisms were genotyped in the
population-representative SAPALDIA cohort. BHR was assessed at baseline by methacholine challenge
and defined as a fall of > or =20% in forced expiratory volume in 1 s. Independent effects of GST
polymorphisms and BHR on new onset of asthma after 11 years of follow-up were estimated by
multiple logistic regression analysis, adjusting for relevant baseline measures. Effect modification was
assessed by including interaction terms in the model. RESULTS: Among 4426 asthma-free participants
at baseline, 14% had BHR. At follow-up, 3.3% reported new onset of physician-diagnosed asthma. BHR
(p<0.001) and GSTP1 Ile105Val genotype (p = 0.005) were independently associated with incident
asthma, but no association was seen for GSTT1 and GSTM1 gene deletion polymorphisms. Among
subjects free of respiratory symptoms at baseline, the effect of BHR on the risk of physician-diagnosed
asthma at follow-up was restricted to GSTP1 105 Ile/Ile carriers (OR 4.57, 95% CI 2.43 to 8.57 vs 1.40,
95% CI 0.58 to 3.39; p for interaction = 0.023). CONCLUSIONS: If confirmed by independent studies,
our results suggest that GSTP1 Ile105Val genotype strongly determines the progression of BHR to
physician-diagnosed asthma in the general population.
doi:10.1136/thx.2007.085555 
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ABSTRACT 
 
Background: Bronchial hyper-responsiveness (BHR) and variation in Glutathione S-
transferase (GST) genes have been associated with asthma risk. We investigated the 
relationship of these two risk factors on adult onset asthma in the general population. 
Methods: GSTP1 Ile105Val single nucleotide polymorphism and GSTM1 and GSTT1 
gene deletion polymorphisms were genotyped in the population-representative 
SAPALDIA cohort. BHR was assessed at baseline by methacholine challenge and 
defined as a ≥ 20% drop in forced expiratory volume in one second. Independent effects 
of GST polymorphisms and BHR on new onset of asthma after eleven years of follow-up 
were estimated by multiple logistic regression analysis adjusting for relevant baseline 
measures. Effect modification was assessed by including interaction terms in the model.  
Results: Among 4426 asthma free participants at baseline 14% had BHR. At follow-up, 
3.3% reported new onset of physician-diagnosed asthma.  BHR (P<0.001) and GSTP1 
Ile105Val genotype (P=0.005) were independently associated with incident asthma, but 
no association was seen for GSTT1 and GSTM1 gene deletion polymorphisms. Among 
subjects free of respiratory symptoms at baseline, the effect of BHR on the risk of 
physician-diagnosed asthma at follow-up was restricted to GSTP1 105 Ile/Ile carriers 
(odds ratio (OR): 4.57 (95% Confidence Interval: 2.43 - 8.57) vs. 1.40 (0.58 - 3.39); P for 
interaction = 0.023).  
Conclusions: If confirmed by independent studies, our results suggest that GSTP1 
Ile105Val genotype strongly determines the progression of BHR to physician-diagnosed 
asthma in the general population.  
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Introduction 
 
Bronchial hyperresponsiveness (BHR) has been recognized as key feature of asthma,[1] a 
complex respiratory disorder characterized by chronic airway inflammation, increased 
mucus formation, airway wall thickening, and airway smooth muscle dysfunction. BHR 
often precedes the development of asthma,[2-4] but not all subjects exhibiting BHR will 
develop complete expression of asthma.[5] Genetic and environmental co-factors may 
promote or in contrast prevent the development of clinically relevant asthma phenotypes 
among subjects with BHR. According to experiments in mice both, airway inflammation 
and remodeling appear to contribute to development, progression, and persistence of 
BHR.[6] Thus genes expressed in bronchial tissue and involved in the modulation of 
inflammation and associated oxidative stress represent valid candidate genes likely to 
play a role as modifiers of asthma development among subjects with BHR. 
 
Glutathione S-transferases (GSTs) are one group of candidate genes. GSTs are phase II 
detoxification enzymes involved in the clearing of tobacco smoke derived and other 
toxicants.[7] In addition, they have anti-oxidative capacities and can affect the systemic 
and local oxidative stress levels.[8]  GSTP1 is the GST gene most abundantly expressed 
in the lungs.[9] Other highly prevalent GST variants are the homozygous gene deletions 
of GSTM1 and GSTT1, which were associated with lung function in the general 
population [10-12] and with respiratory disease.[13, 14] 
 
We have previously reported that baseline BHR, including silent BHR (i.e. BHR without 
concurrent report of respiratory symptoms), increases the likelihood of an incident 
asthma diagnosis within 11-years of follow-up in the population-based adult SAPALDIA 
cohort.[3] We now investigate whether genetic variation in GSTP1, GSTM1, and GSTT1 
modifies the association of BHR with the development of asthma. In particular, a GSTP1 
Ile/Val single nucleotide polymorphism at the amino acid residue 105 results in different 
enzymatic efficiency.[15] GSTP1 105Val hetero- or homozygous carriers have been 
shown to experience a protective effect against asthma [16] and atopic airway 
inflammation. [17] We therefore hypothesized that the risk increasing effect of BHR 
would be stronger among homozygous GSTP1 105 Ile carriers, and wanted to answer this 
question in a large population-based study.  
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METHODS 
 
Study population 
The SAPALDIA cohort, Swiss Study on Air Pollution And Lung and heart Disease In 
Adults, a prospective multicenter study, representative of the adult Swiss general 
population, investigates environmental and genetic factors determining lung health. 
Ethical approval for the study was given by the central ethics committee of the Swiss 
Academy of Medical Sciences and the Cantonal Ethics Committees for each of the eight 
examination areas. Baseline and follow-up examinations eleven years later have 
previously been described in detail.[18, 19] 
Briefly, 9561 subjects predominantly of European-Caucasian ethnicity, aged 18-60 years 
were examined at baseline (1991). 8047 (84%) agreed to participate fully or partly at the 
follow-up survey (2002). Information on health and life style was collected by computer-
assisted personal interview at both time points. Lung function was evaluated using the 
same spirometer devices (Sensormedics model 2200, Yorba Linda, USA) at both time 
points.[20] Skin reactivity to eight common airborne allergens was assessed by skin prick 
test at baseline. Circulating serum levels of total IgE and Phadiatop test for detection of 
allergen-specific IgE were measured at baseline using the CAP FEIA system (Pharmacia 
Diagnostics, Uppsala, Sweden). Blood for DNA extraction and informed consent to 
genetic testing was collected at follow-up.  
 
 
Methacholine challenge 
 
BHR was assessed by methacholine challenge (Provocholine® , Roche, Nutley, New 
Jersey, USA) in 7126 participants at baseline. Increasing concentrations of methacholine 
(0.39, 1.56, 6.25, and 25.0 mg/ml solutions in a phosphate buffer without phenol) were 
administered through an aerosol dosimeter (Mefar MB3, Bovezzo, Italy).[21]  The 
presence of BHR was defined as a 20% or greater drop in FEV1 up to a cumulative dose 
of 2mg (8.37µmol). The methacholine responsiveness was determined for each subject by 
calculating individual dose-response slopes similar to the method suggested by O’Connor 
et al. [22, 23] The slope was then defined as the ratio between the percentage decline in 
FEV1 and the total cumulative dose of methacholine. 
 
Definition of asthma incidence, respiratory symptoms, and selected covariates 
Incident asthma cases were defined as new asthma reports when participants without 
asthma at baseline answered at follow-up “Yes” to both questions: “Have you ever had 
asthma?” and “Was this confirmed by a doctor?”.  
Current asthma symptoms were defined by a self-report of physician-diagnosed asthma 
and a positive answer to at least one of the following questions: "Are you currently taking 
any medicine for asthma?" and "Have you had an attack of asthma in the last 
12 months?".  
Atopy was defined as a positive skin prick test reaction to at least one common allergen 
tested.[24] Occupational exposure to inhalant irritants was assessed by asking “Have you 
ever worked in a job which exposed you to vapours, gas, dust or fumes?”. Smokers were 
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participants who had smoked ≥ 20 packs of cigarettes or ≥ 360 g of tobacco in their 
lifetime.[18, 19, 25] Former smokers at baseline or follow-up were smokers who had quit 
smoking at least 1 month before the examination. Current smokers reported active 
smoking at the interview. The amount of cigarette exposure of participants was assessed 
by pack-years. Environmental tobacco smoke (ETS) was defined by a positive answer to 
the question “Have you been regularly exposed to tobacco smoke in the last 12 months? 
(„regularly“ means on most days or nights)?” . 
 
Genotyping 
Whole blood was sampled at follow-up and DNA was extracted manually [19] using the 
Gentra™ Puregene Kit (GENTRA Systems, Minneapolis, USA). Genotyping of the 
GSTP1 Ile105Val single nucleotide polymorphism and the gene deletion polymorphisms 
for GSTM1 and GSTT1 was performed by TaqMan® methodology as previously 
described.[12] Hardy-Weinberg equilibrium (HWE) for the GSTP1 Ile105Val 
polymorphism was tested using Arlequin Version 2.000 [26] and genotype distribution 
was found to be in HWE. Genotype frequencies did not differ by Swiss language region 
or subjects’ nationality. 
 
Study sample  
We included in the present analysis SAPALDIA participants with valid spirometry and 
bronchial challenge data from the baseline examination and questionnaire data who 
participated in the interview at follow-up (n=5825; see supplementary online Figure 1). 
Valid information on respiratory health status at baseline and follow-up as well as 
genotype information on the GST polymorphisms was available from 4682 of these 
participants. Subjects who had reported physician-diagnosed asthma at baseline were 
excluded (n=256). The final sample size for this study consisted of 4426 SAPALDIA 
participants. Missing information for covariates: baseline FVC (n=105), atopy (n=99), 
pack-years smoked during follow-up (n=112), ETS exposure (n=5), occupational inhalant 
exposure (n=332) reduced the study sample available for multiple regression analysis to 
3806 subjects of which 3.1% reported for the first time physician-diagnosed asthma at 
follow-up (n=119). 
 
Statistical analysis 
Differences in genotype frequency between cases and controls were assessed by Chi2 
test. The associations between GST genotypes and bronchoconstrictor response slope 
measured as % FEV1 drop per µmol methacholine at baseline were assessed by multiple 
linear regression adjusting for baseline information on FEV1, FEV1 squared, study area, 
sex, age, BMI, atopy, smoking status and pack-years smoked; predicted values for 
GSTP1 Ile105Val genotypes were displayed using the box plot command. The effects of 
BHR at baseline and GST genotypes on the risk for reporting new physician-diagnosed 
asthma and current asthma symptoms at follow-up were estimated using multiple logistic 
regression analysis adjusted for sex, age, study area, baseline measures of FVC and body 
mass index (BMI), weight change during follow-up, and follow-up information on 
smoking status, amount of pack-years smoked, ETS and occupational dust, fumes and 
vapors exposure. Modification of the effect of baseline BHR on incident asthma reports 
by GSTP1 Ile105Val genotype was assessed by including a multiplicative interaction 
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term in the model, as well as by stratifying analysis by genotype. Cumulative asthma 
incidences (95% CI) in subgroups defined by combinations of GSTP1 Ile105Val 
genotypes and baseline BHR were calculated using the adjust command after multivariate 
logistic regression analysis. Two-sided p-values of <0.05 and <0.10 were considered as 
statistically significant for main effects and interactions.[27] All analyses were conducted 
using STATA SE version 9.1 (Stata Corporation, TX, USA).  
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RESULTS 
The characteristics of the study population over all and stratified by the presence or 
absence of baseline BHR are presented in Table 1. Among the 4426 participants free of 
asthma at baseline 3.3% (n=144) reported a history of physician-diagnosed asthma at the 
follow-up examination. 
 
Fourteen percent of the study sample had BHR at baseline; women were overrepresented 
in the group exhibiting BHR. Lung function was lower and the proportion of subjects 
with FEV1/FVC <0.70 higher in the subgroup with BHR. Smokers were more likely to 
have BHR and the mean amount of pack-years smoked was higher in subjects with BHR, 
whereas no difference in ETS exposure or occupational exposure to gas, dust, and fumes 
was noted between the two BHR groups. Baseline respiratory symptoms such as 
wheezing, chronic cough and phlegm, and shortness of breath at night were more 
prevalent in the group with BHR; 19.7% of subjects with BHR reported at least one 
respiratory symptom compared to only 11.5% of participants without BHR. The GST 
genotype distributions agreed well with those previously reported in other Caucasian 
populations.[13, 16, 28]  
 
Earlier reports suggested that GSTP1 genotype might be associated with BHR.[16] Table 
1 shows that the distribution of the various GSTP1 Ile105Val genotypes was not 
materially different among participants with or without BHR. Homozygous Ile-carriers 
were slightly underrepresented among subjects with baseline BHR, but the difference did 
not reach statistical significance (44.6% vs. 47.2%; P=0.23; Table 1). We also compared 
the adjusted methacholine dose response according to GST genotypes (Figure 1). No 
difference in response to the bronchoconstrictor was observed between the three GSTP1 
Ile105Val genotypes. GSTM1 and GSTT1 genotypes were not associated with response to 
methacholine (data not shown). Homozygous GSTP1 Ile/Ile genotypes were slightly 
overrepresented among subjects with asthma at baseline (p=0.06). Neither GSTM1 nor 
GSTT1 genotype was associated with self-reported physician-diagnosed asthma at 
baseline (see supplementary online Table 1).  
 
In Table 2, we present the unadjusted association of both, GST genotypes and baseline 
BHR with physician-diagnosed asthma at follow-up. Both, baseline BHR and GSTP1 
Ile105Val genotype, but not GSTM1 or GSTT1 gene deletion polymorphisms were 
associated with new asthma reports at follow-up (P<0.001 for baseline BHR and P=0.005 
for GSTP1 genotype). The independent associations of baseline BHR and GSTP1 
genotype with physician-diagnosed asthma at follow-up were confirmed after adjustment 
for potential confounders and mutual adjustment for each other (Figure 2).  The adjusted 
odds ratio (OR (95% CI)) for BHR vs. no BHR was 3.52 (2.31 - 5.35; P<0.001) and for 
GSTP1 105Ile/Ile vs. GSTP1 105Val genotypes it was 1.71 (1.17 - 2.50; P=0.006).  
 
The BHR effect on new reports of asthma and asthma symptoms was modified by GSTP1 
(Table 3). The effect of baseline BHR on the risk for new reports of asthma was stronger 
among GSTP1 Ile/Ile genotype (OR: 4.84 (95%CI: 2.28 - 8.49) vs. 2.42 (1.25 - 4.67); P 
for interaction between BHR and GSTP1 Ile105Val genotype PBHR*GSTP1  = 0.117. The 
effect modification by GSTP1 genotype reached statistical significance after exclusion of 
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subjects reporting at least one respiratory symptom at baseline (OR: 4.57 (2.43 - 8.57) vs. 
1.40 (0.58 - 3.39); PBHR*GSTP1=0.023). Comparable interactions between GSTP1 genotype 
and baseline BHR were observed for self-reported asthma symptoms at follow-up. Again, 
the BHR effect was stronger among homozygous GSTP1 Ile/Ile genotypes than GSTP1 
105Val carriers and reached statistical significance after exclusion of subjects reporting at 
least one respiratory symptom at baseline (OR: 15.86 (5.32 - 47.26) vs. 1.95 (0.71 - 6.96); 
PBHR*GSTP1=0.033). No modification of the BHR/asthma association by GSTT1 or GSTM1 
gene deletion was observed (data not shown).   
 
The adjusted 11-year cumulative incidence of self-reported physician-diagnosed asthma 
was 14 cases per 1000 persons (95% CI: 9 - 21 per 1000) among subjects without 
baseline BHR and no GSTP1 Ile/Ile genotype; 19 cases (13 – 28 per 1000) among 
subjects without BHR, but with GSTP1 Ile/Ile genotype; 21 cases (9 – 45 per 1000) 
among subjects with BHR and no GSTP1 Ile/Ile genotype; and 95 cases (59 – 150 per 
1000) among subjects with both, baseline BHR and GSTP1 105Ile/Ile genotype. Thus, 
among participants with baseline BHR in this study population the excess number of 
incident asthma cases due to GSTP1 Ile/Ile genotype was 74/1000 persons over the 11-
year follow-up period.  
 
Since GST genotypes have previously been associated with lung growth in children [10] 
and with lung function in adults, [12, 14] we performed a sensitivity analysis and omitted 
the adjustment for baseline lung function from all statistical models. None of the effects 
presented were materially altered (data not shown). 
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DISCUSSION 
            We present evidence that adults with BHR and GSTP1 Ile/Ile genotype are at an 
increased risk to develop asthma.  Furthermore, genetic variation in GSTP1, but not 
GSTM1 or GSTT1 modifies the risk of BHR progression to asthma in the general 
population. As GSTP1 exhibits the highest lung tissue expression of the three GST 
enzymes, our results are in line with the hypothesis that the extent of local inflammation 
in the airways contributes to airway remodelling and thus to the association between 
BHR and adult-onset asthma.  
Airway smooth muscle dysfunction [29-31]  and increased airway wall thickening 
[32, 33] caused by airway remodelling is commonly thought to underlie BHR and 
possibly its progression to asthma.  Prolonged or repeated exposure to airway irritants 
(i.e. tobacco smoke, ambient air pollution or occupational activity derived particles) can 
cause airway dysfunction of the smooth muscle and the bronchial epithelium through the 
induction of chronic airway inflammation.[21, 34, 35] BHR itself contributes to a 
harmful circle of sustained inflammation, since the associated abnormal airflow resulting 
from the reduced airway caliber alters the deposition profile of inhalants in the airways. 
[36-39] Hence it seems probable that increased depositions of particles with mostly 
oxidative properties will result in sustained airway inflammation and oxidative stress. 
This view is corroborated by recent SAPALDIA results showing that BHR increased the 
effect of ETS exposure on the incidence of asthma-related symptoms. [3, 40] 
 
            According to our results, the genetic make-up of a person co-determines the 
exposure load necessary to induce sustained inflammation, oxidative stress, and airway 
remodelling in the bronchial tissue. The modifying effect of the GSTP1 Ile105Val 
genotype may reflect the different, but related roles of this enzyme, i.e. in phase II 
detoxification of tobacco- or air pollution-derived chemicals,[7] in oxidant defense,[41]  
and in cell cycle regulation.[42] Lower GSTP1 activity in bronchial tissue is likely to 
result in decreased detoxification of airway irritants, in enhanced inflammation and 
oxidative stress causing sustained airway wall thickening and smooth muscle 
dysfunction. This hypothesized pathophysiological mechanism is supported by evidence 
about the direct involvement of GSTP1 in the regulation of C-JUN N- terminal protein 
kinase (JNK) and down stream processes, which lead to increased cell proliferation in 
response to oxidative stress.[43, 44] Mice deficient for GSTP1 activity are prone to 
increased tumorigenesis upon exposure to polycylic hydrocarbon exposure.[45] The 
modifying effect of GSTP1 in the BHR/asthma association may therefore result from the 
central role of this enzyme and oxidative stress in apoptotic processes. 
            Previous evidence supports the hypothesis that the degree of airway inflammation 
and oxidative stress contributes to BHR progression. First, in utero exposure to maternal 
smoking increases the risk of progression from BHR to asthma.[46] Passive smoking has 
been identified to confer increased oxidative stress locally in bronchial tissue as well as 
systemically in exposed subjects.[47-49] Second, obesity characterized by increased 
systemic inflammation has been associated with increased progression of BHR and 
asthma.[31] Third, Cheng et al. found a gradient of free radical concentrations in nasal 
polyps (NP), an inflammatory chronic disease frequently associated with BHR and 
asthma.  Concentrations were lowest in NP cases without BHR and asthma, intermediate 
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in NP cases with concurrent silent BHR, and highest in NP cases with concurrent BHR 
and asthma.[50]  
Genetic GST variants have previously been associated with asthma in different, 
exclusively cross-sectional studies. The prevalence of the GSTP1 105Val allele was 
lower in patients with asthma,[51, 52] BHR [16] and asthmatics with severe disease.[16, 
17, 53, 54] Our findings extend this observation and indicate that the GSTP1 105Ile/Ile 
genotype, which is carried by about 47% of our European-Caucasian population, 
represents a prevalent asthma risk factor in the general adult population. The absence of a 
cross-sectional GSTP1/BHR association in our population-based study contrasts the 
positive association by Fryer and colleagues [16].  Their study had recruited volunteers 
and patients from respiratory clinics. Female subjects were overrepresented (>70%).  
Women are known to be more susceptible to bronchoconstrictor challenge, [16, 23] 
although in the SAPALDIA cohort the GSTP1/BHR association was not modified by 
gender (data not shown). Our lacking association of GSTM1 and GSTT1 gene deletion 
with asthma occurrence also contrasts some previous results.  A few small case-control 
studies suggest that the prevalence of GSTM1 and GSTT1 gene deletions is increased in 
asthmatics with concurrent atopy.[55, 56] In a limited number of cohorts, GSTM1 and 
GSTT1 deficiency increased the risk for asthma, asthma-related symptoms and low lung 
function during childhood in combination with in utero and/or current passive smoking 
exposure.[10, 11, 57] Protective effects of anti-oxidant supplementation on the lung 
function of asthmatic children exposed to high ambient ozone were restricted to GSTM1-
deficient participants.[58] The discrepancy between our study and previous reports with 
regard to the role of GSTM1 and GSTT1 deletions might partly be related to differences 
in study population, sample size, study design, or inhalant exposures. Most importantly, 
we focused on adult incident asthma, whereas evidence for a GSTM1 or GSTT1/asthma 
association was most consistently found in children. Unfortunately, our sample size was 
insufficient to additionally stratify the results by atopy or exposure to environmental 
inhalants including ETS.  
 
             The strength of the present study is its prospective design, which allowed us to 
investigate long term effects of BHR in the general population. The large sample size of 
the cohort and its detailed characterization made it possible to investigate the interaction 
between BHR and GST genotypes on incidence of adult onset asthma. In addition it was 
possible to refine the analysis after exclusion of participants who might have had asthma 
symptoms at baseline without the formal diagnosis of asthma. Nevertheless, the number 
of new asthma cases available to estimate the effect modification of baseline BHR by the 
GSTP1 genotype was limited. Independent studies thus needed to confirm our novel 
finding. 
 
  
            The definition of asthma in the present study relied solely on the self-report of 
asthma phenotypes. Asthma status may therefore be subject to misclassification.[59, 60] 
The unknown degree of population stratification is another limitation, as no panel of 
anonymous markers was tested to assay the population admixture of the Swiss general 
population. But stratification of the associations by study centre, language region, and 
nationality did not materially alter the main findings, suggesting a minor influence of 
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population stratification at best. We cannot exclude participation bias. Participants at 
baseline were less likely to be of intermediate age or of Swiss nationality, but were more 
likely to be former smokers and to report asthma or wheezing than non-participants.[18, 
19] Unlike participation at baseline, asthmatics were less likely to participate at follow-
up.[3, 19] Slightly more males, smokers, subjects with low educational background, with 
occupational exposure to fumes, gas and dust, and with respiratory symptoms were non-
participants at the follow-up examination. No difference was noted for atopy and BHR 
between participants and non-participants at follow-up. Subjects with low lung function, 
a risk factor for BHR,[61] were less likely to undergo methacholine challenge,[3]  but we 
had previously presented results from the SAPALDIA cohort that in contrast to previous 
evidence [14] GSTP1 was not associated with lung function in this adult sample from the 
general population.[12] In the absence of genotype information on non-participant at 
baseline and follow-up we cannot analyze whether we failed to include subjects with 
unique genotype/phenotype combinations. Even though it is unlikely that genotype status 
influenced participation, this possible source of bias also points to the need for 
independent studies to confirm our result. 
 
 In conclusion, we present evidence that the GSTP1 Ile/Ile genotype may be a 
strong and prevalent risk factor for the progression of silent BHR to asthma in the general 
population. If confirmed by additional studies, the results are consistent with genetic 
variation in local metabolism of inhalant derived chemicals and/or free radicals playing a 
relevant role in the progression from BHR to asthma.  
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FIGURES AND TABLES 
 
Figure 1:  Distribution of predicted adjusted* baseline methacholine dose response 
slope in relation to GSTP1 genotype. 
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* adjusted for area, sex, age, baseline information on FEV1, FEV1 squared, BMI, atopy, 
smoking status and pack-years smoked  
 
 on 24 February 2009 thorax.bmj.comDownloaded from 
 19
 
 
Figure 2: Adjusted* risk for self-report of physician-diagnosed asthma in relation to 
baseline BHR as well as GSTP1 Ile105Val, GSTM1 or GSTT1 gene deletion 
polymorphisms.  
 
1
3
5
OR
Baseline BHR
vs. no BHR
GSTP1 Ile/Ile
vs. GSTP1 Ile/Val 
or Val/Val
GSTM1 null
vs. GSTM1 non-null
GSTT1 null
vs. GSTT1 non-null
P<0.001
P=0.006
1.71
3.52
 
* Adjusted for baseline FVC, BMI, age, sex, study area, weight change during follow-up, 
smoking status at follow-up, pack-years smoked to follow-up, ETS exposure at follow-
up, occupational gas/dust/fume exposure at follow-up. BHR effect was additionally 
adjusted for the three GST genotypes; GST genotype effects additionally adjusted for 
baseline BHR. 
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Supplementary Figure 1: SAPALDIA participants and study population. 
 
 
* Exclusion criteria for bronchial challenge (Brutsche, 2006 Thorax) 
† For Comparison of cohort participants with the subjects having only participated at 
baseline examination see Brutsche 2006 Thorax (Table 1). 
‡ Of these 144 reported physician-diagnosed asthma at follow-up (3.3%) 
¶ Of these 119 reported physician-diagnosed asthma at follow-up (3.1%) 
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Table 1: Characteristics* of the study population, overall and stratified by presence 
or absence of baseline BHR. 
  ALL Without BHR  With BHR  
Cohort participants included in study N (%) 4426 (100) 3800 (85.9) 626 (14.1) 
Women [N (%)] 2169 (49.0) 1758 (46.3) 411 (66.7) 
Baseline characteristics    
Age at baseline [yr, mean (±SD)] 40.5 (11.3) 40.3 (11.2) 41.4 (11.7) 
BMI at baseline [kg/m2] 23.7 (3.5) 23.6 (3.4) 23.9 (4.0) 
Total IgE  >100 kU/L [N (%)] 821 (20.1) 657 (18.6) 164 (29.3) 
Atopy [N (%)] 908 (21.0) 680 (19.6) 159 (28.0) 
Methacholine response slope [geometric mean (±SD)] ¶ 1.0 (3.7) 0.7 (2.9) 7.1 (2.8) 
Non smokers [N (%)] 2069 (46.8) 1780 (46.9) 289 (46.3) 
Former smokers [N (%)] 1016 (23.0) 900 (23.7) 116 (18.6) 
Current smokers [N (%)] 1337 (30.2) 1118 (29.4) 219 (35.1) 
Pack-years among ever smokers at baseline[mean (±SD)] 16.5 (17.7) 16.0 ( 17.3) 19.7 (19.6) 
ETS exposure  reported at baseline [N (%)] 879 (19.9) 757 (19.9) 122 (19.6) 
Gas, fumes and dust exposure at work at baseline [N (%)] 1348 (30.6) 1144 (30.2) 204 (32.6) 
FEV1 % pred. [%, mean (±SD)]  101.6 (12.2) 102.7 (11.8) 94.7 (12.1) 
FVC [L, mean (±SD)]  4.6 (1.0) 4.7 (1.0) 4.2 (1.0) 
FEV1/FVC [%, mean (±SD)]  79.8 (6.8) 80.2 (6.6) 77.3 (7.2) 
FEV1/FVC  <0.7 [N (%)] 324 (7.5) 232 (6.3) 92 (15.0) 
Wheezing without cold last 12 months [N (%)] 207 (4.7) 149 (3.9) 58 (9.3) 
Chronic phlegm [N (%)] 222 (5.1) 181 (4.8) 41 (6.7) 
Chronic cough [N (%)] 157 (3.6) 119 (3.1) 38 (6.1) 
Woken up at night by shortness of breath [N (%)] 117 (2.6) 94 (2.5) 23 (3.7) 
≥ one of  respiratory symptoms above [N (%)] 561 (12.7) 438 (11.5) 123 (19.7) 
    
Selected follow-up characteristics    
BMI at follow-up  [kg/m2] 25.7 (4.2) 25.7 (4.1) 26.1 (4.9) 
Weight change during follow-up [kg, mean (±SD)] 5.6 (6.1) 5.5 (6.1) 5.7 (6.3) 
Never smokers [N (%)] 1905 (43.0) 1631 (43.0) 267 (43.0) 
Ever smokers [N (%)] 2521 (57.0) 2164 (57.0) 357 (57.0) 
Pack-years [mean (±SD)] ∏ 6.1 (7.6) 6.0 (7.6) 7.0 (7.8) 
ETS exposure reported at follow-up [N (%)] 585 (13.2) 507 (13.3) 78 (12.5) 
Gas, fumes and dust exposure at work at follow-up [N (%)] 1143 (27.9) 1013 (28.7) 130 (22.9) 
    
GST genotypes    
GSTP1 Ile105Val   [N (%)]    
            Ile/Ile 2071 (46.8) 1792 (47.2) 253 (44.6) 
            Ile/Val 1945 (43.9) 1650 (43.4) 266 (46.9) 
            Val/Val 410 (9.3) 358 (9.4) 48 (8.5) 
            Ile/Val or Val/Val 2355 (53.2) 1828 (52.5) 314 (55.4) 
GSTM1  [N (%)]    
           no homozygous deletion 2100 (47.5) 1802 (47.5) 298 (47.7) 
           homozygous deletion 2322 (52.5) 1995 (52.5) 327 (52.3) 
GSTT1  [N (%)]    
           no homozygous deletion 3600 (81.4) 3090 (81.4) 510 (81.6) 
           homozygous deletion 822 (18.6) 707 (18.6) 115 (18.4) 
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* Given as absolute numbers and percentages for categorical variables and as mean ± 
standard deviation (±SD) for continuous variables.  
† Numbers do not consistently add up to full sample size due to missing information on 
some of the presented characteristics 
‡ Atopy was defined as a positive skin prick test reaction to at least one common allergen  
 ¶ % decrease in FEV1 per µmol Methacholine challenge 
∏ Pack years smoked during follow-up among ever smokers  
 
 
 
 
 
 
 
 
 
 
 
Table 2:  Unadjusted association of baseline BHR and GST genotypes with self-
report of physician-diagnosed asthma after eleven year follow-up  
 
  
Subjects at risk 
at baseline 
New asthma 
reports 
P for 
difference  
Baseline BHR    
Without BHR  3800 94/ 2.5%  
With BHR  626 50/ 8.0% <0.001 
 
 
  
GSTP1 Ile105Val    
Ile/Val or Val/Val 2355 60/ 2.6%  
Ile/Ile 2071 77/ 4.0% 0.005 
    
GSTM1    
no deletion 2100 71/ 3.4%  
deletion 2322 73/ 3.1% 0.66 
    
GSTT1    
no deletion 3600 119/ 3.3%  
deletion 822 25/ 3.0% 0.70 
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Table 3: Adjusted risk* for self-report of physician-diagnosed asthma and asthma symptoms at follow-up in relation to BHR at 
baseline, stratified by GSTP1 Ile105Val genotype.  
 
 
GSTP1 Ile/Ile GSTP1 Ile/Val or Val/Val Interaction 
  
Subjects at 
risk  
Cases  
 OR 95% CI P-Value 
 Subjects at 
risk  
 
 
Cases 
 OR 95% CI  P-Value P-Value‡ 
physician-diagnosed 
asthma              
Without BHR 1551 42 1    1729 35 1     
With  BHR 232 27 4.84 2.28 8.49 <0.001 294 15 2.42 1.25 4.67 0.009 0.117 
   
   
   
     
current asthma 
symptoms              
Without BHR 1551 10 1    1729 13 1     
With  BHR 232 16 14.7 5.76 37.36 <0.001 294 9 4.06 1.59 10.40 0.003 0.115 
              
After exclusion of baseline symptomatics† 
physician-diagnosed 
asthma              
Without BHR 1384 37 1    1524 30 1     
With  BHR 186 21 4.57 2.43 8.57 <0.001 236 7 1.40 0.58 3.39 0.45 0.023 
   
   
   
    
 
current asthma 
symptoms              
Without BHR 1384 9 1    1524 12 1     
With  BHR 186 11 15.86 5.32 47.26 <0.001 236 4 1.95 0.71 6.96 0.29 0.033 
                            
 
* adjusted for baseline measures of FVC and BMI, weight change during follow-up, sex, age, smoking status (never/persistent/others), pack-
years smoked to follow-up, ETS (follow-up) and occupational dust/fumes/vapors exposure (follow-up), study area.  
† Subjects excluded (n=476) who reported at baseline at least one of the following respiratory symptoms: wheezing without a cold; chronic 
cough; chronic phlegm; woken up by shortness of breath at night.  
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‡ P-values for interaction between BHR and GSTP1 Ile105Val genotype obtained by including multiplicative interaction term in multiple 
logistic regression analysis 
 
Supplementary online Table 1: Unadjusted association of GST genotypes with baseline physician-diagnosed asthma. 
 
  All Baseline asthma 
 N=4682 N=256 
GSTP1 Ile105Val   
Ile/Val or Val/Val 2478 (52.9%) 121 (47.3%) 
Ile/Ile 2204 (47.1%) 135 (52.7%) 
P-value  0.063 
   
GSTM1   
no deletion 2234 (47.7%) 132 (51.6%) 
deletion 2448 (52.3%) 124 (48.4%) 
P-value  0.205 
   
GSTT1   
no deletion 3818 (81.6%) 215 (84.0%) 
deletion 864 (18.4%) 41 (16.0%) 
 P-value    0.302 
   
 
 
 o
n
 24 February 2009 
thorax.bmj.com
D
ow
nloaded from
 
 on 24 February 2009 thorax.bmj.comDownloaded from 
 on 24 February 2009 thorax.bmj.comDownloaded from 
